Protein kinase C in Lung Cancer with mutant EGFR
Protein kinase C in Lung Cancer with mutant EGFR
批准号:
9888660
负责人:
YUSUF AWNI HANNUN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-01 至 2024-03-31
关键词:
AcuteCancer BiologyCell LineCell membraneCellsCritical PathwaysDataDevelopmentDiglyceridesDrug resistanceEnzymesEpidermal Growth Factor ReceptorEvolutionFRAP1 geneFamilyFoundationsG-Protein-Coupled ReceptorsGoalsGrowthGrowth FactorIsoenzymesLaboratoriesLightLipidsLung AdenocarcinomaMalignant NeoplasmsMalignant neoplasm of lungMediatingMembraneMutationOncogenicOrangesPDPK1 genePathway interactionsPatientsPharmacologyPhospholipase CPhosphorylationPlayPreventionPropertyProtein InhibitionProtein Kinase CProtein translocationProteinsReceptor Protein-Tyrosine KinasesReceptor SignalingRegulationRelapseResistanceRoleSchemeSignal PathwaySignal TransductionSignaling ProteinTestingTherapeuticTumor PromotersWorkcancer cellcell behaviorcell growthin vivoinhibitor/antagonistmembermutantnovelnovel therapeuticsoutcome forecastoverexpressionpreventprotein activationprotein expressionreceptorresponsetargeted treatmenttumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Mutant EGFR (mEGFR) is a key driver of a subset of lung adenocarcinoma that is targetable by specific
inhibitors; however, responses are transient, and patients almost always relapse, thus necessitating a deep
understanding of the mechanisms involved in the action of mEGFR. Our studies are leading to the discovery of
rewiring of EGFR signaling in mEGFR with a pivotal role played by protein kinase C (PKC). We find that patients
with tumors having mEGFR often show a selection for very high levels of PKC, and these patients have
substantially worse prognosis, further underscoring the need to study PKC. We find that this enhanced
expression of PKC results in its sustained activation which then results in the activation of Akt, mTOR, and other
downstream targets. This proposal will focus on developing and testing the hypothesis that cancers with
mEGFR require independent selection for high expression and sustained activation of PKC which then plays a
key role in allowing oncogenic signaling and growth by mEGFR. We will pursue the following specific aims: Aim
1. Define the sustained activation of PKC in response to mEGFR and the role of PKC in mediating key
signaling functions of mEGFR and elucidate key mechanisms. We will establish the activation of PKC and
define its roles in mediating the activation of Akt and mTOR in mEGFR cells and determine if and how the
induction of cPKC switches signaling downstream of mEGFR. We will also define the mechanisms involved.
Aim 2. Define the role of PKC in mediating oncogenic responses to mEGFR. Here will evaluate the
hypothesis that hyper-activation of PKC in mEGFR lung cancers mediates critical oncogenic properties in cells
and in vivo. Taken together, these results are beginning to define a novel coordinated pathway of oncogenesis
in those cancers that become addicted to the PKC pathway. Moreover, these novel results may constitute a
paradigm shift in our understanding of mechanisms regulating PKC and its significance to cancer biology and
therapeutics, especially in preventing emergence of resistance to EGFR inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein kinase C in Lung Cancer with mutant EGFR
-
批准号:10618917
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Protein kinase C in Lung Cancer with mutant EGFR
-
批准号:10454776
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Ceramide Activated Protein Phosphatases
-
批准号:10208802
-
项目类别:
-
资助金额:$36.49万
-
财政年份:2018
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Ceramide Activated Protein Phosphatases
-
批准号:10434893
-
项目类别:
-
资助金额:$35.76万
-
财政年份:2018
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Ceramide Activated Protein Phosphatases
-
批准号:10734669
-
项目类别:
-
资助金额:$39.54万
-
财政年份:2018
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral Sphingomyelinases and Bioactive Ceramides
-
批准号:10437811
-
项目类别:
-
资助金额:$73.6万
-
财政年份:2016
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral Sphingomyelinases and Bioactive Ceramides
-
批准号:10640899
-
项目类别:
-
资助金额:$73.6万
-
财政年份:2016
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral sphingomyelinases and bioactive ceramides
-
批准号:9071506
-
项目类别:
-
资助金额:$70.92万
-
财政年份:2016
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Diversity Supplement for Bernandie Jean: Neutral sphingomyelinases and bioactive ceramides
-
批准号:9752140
-
项目类别:
-
资助金额:$5.97万
-
财政年份:2016
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Admin Supplement: Neutral Sphingomyelinases and Bioactive Ceramides
-
批准号:10797322
-
项目类别:
-
资助金额:$4.86万
-
财政年份:2016
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral Ceramidase in Colon Cancer
-
批准号:8577881
-
项目类别:
-
资助金额:$33.88万
-
财政年份:2013
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral Ceramidase in Colon Cancer
-
批准号:9081550
-
项目类别:
-
资助金额:$32.53万
-
财政年份:2013
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Neutral Ceramidase in Colon Cancer
-
批准号:8848356
-
项目类别:
-
资助金额:$32.53万
-
财政年份:2013
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
MOLECULAR IDENTITY OF MATURE LYSOSOMAL ACID SPHINGOMYELINASE
-
批准号:8365895
-
项目类别:
-
资助金额:$1.28万
-
财政年份:2011
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Thermo TSQ Quantum Access Mass Spectrometer
-
批准号:7794261
-
项目类别:
-
资助金额:$25.68万
-
财政年份:2010
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Support for the Charleston Ceramide Conference
-
批准号:8434291
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Support for the Charleston Ceramide Conference
-
批准号:8423722
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2009
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Support for the Charleston Ceramide Conference
-
批准号:8015580
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2009
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Support for the Charleston Ceramide Conference
-
批准号:7761251
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
Support for the Charleston Ceramide Conference
-
批准号:7614131
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2009
-
负责人:YUSUF AWNI HANNUN
-
依托单位:
海外基金